Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 2/20 | 0.50 |
| ▸ | EDNRA | P25101 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7943949 | 0.84 | EDNRB (0.67) | EDNRBEDNRASMN1; SMN2LMNA | |
| SCHEMBL1771745 | 0.81 | SLC6A4 (0.45) | — | |
| SCHEMBL1771810 | 0.76 | NOTUM (0.38) | SMN1; SMN2LMNAMEN1KMT2AGAA | |
| SCHEMBL8307972 | 0.76 | EDNRA (0.78) | EDNRBEDNRA | |
| SCHEMBL1772580 | 0.75 | SMN1; SMN2 (0.54) | SMN1; SMN2LMNAMEN1KMT2AGAA | |
| SCHEMBL31454786 | 0.74 | MAPK9 (0.55) | EDNRBEDNRASMN1; SMN2LMNAMEN1 | |
| SCHEMBL8411485 | 0.71 | GAA (0.46) | EDNRBEDNRASMN1; SMN2LMNAGAA | |
| SCHEMBL10707970 | 0.69 | GAA (0.47) | EDNRBEDNRASMN1; SMN2LMNAGAA | |
| SCHEMBL15091787 | 0.69 | L3MBTL1 (0.65) | EDNRBEDNRASMN1; SMN2MEN1KMT2A | |
| SCHEMBL8622189 | 0.68 | EDNRB (0.61) | EDNRBEDNRAMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2326634-B1 | CHROMENE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2014-11-05 | — | — | EP | disclosed |
| US-20140235672-A1 | CHROMENE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2014-08-21 | — | — | US | disclosed |
| US-8759390-B2 | Chromene modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-24 | — | — | US | disclosed |
| CN-102159562-A | Chromene modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO | 2011-08-17 | — | — | CN | disclosed |
| EP-2326634-A1 | CHROMENE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20110112146-A1 | CHROMENE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-12 | — | — | US | disclosed |
| WO-2010009069-A1 | CHROMENE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235672-A1 | CHROMENE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR3, CCR2 | EDNRB 361/4885EDNRA 373/4885SMN1; SMN2 3612/4885 |
| US-20110112146-A1 | CHROMENE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR3, CCR2 | EDNRB 349/4885EDNRA 377/4885SMN1; SMN2 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.